MD of Bharat Biotech said - no family member joined political party, our company has vaccine experience | Bharat Biotech MD said - Some people are gossiping on our vaccine, we are a global company with experience. » India News
Connect with us

India News

MD of Bharat Biotech said – no family member joined political party, our company has vaccine experience | Bharat Biotech MD said – Some people are gossiping on our vaccine, we are a global company with experience.



  • Hindi news
  • National
  • MD of Bharat Biotech Said No Family Member Joined Political Party, Our Company Has Vaccine Experience

Fed up with Ads? Install Dainik Bhaskar app for news without ads

new Delhi23 minutes ago

  • Copy link

Krishna Alla, MD, Bharat Biotech, answered the questions of the reporters at the press conference.

Kovaxin of Bharat Biotech has been approved by the Drug Controller General of India (DCGI) for emergency use. The opposition has alleged that this approval has been given in haste. In the midst of the ongoing politics on the vaccine, Bharat Biotech MD Krishna Alla has put his side. Alla said that the politics is happening on the vaccine. Some people are only gossiping about our vaccine. It should not happen.

Ella said, ‘I want to make it clear that no member of my family is associated with any political party. He also said that we have experience in making vaccines.

India Biotech’s MD on politics

  • We are global company: Krishna Alla said, ‘We are not doing clinical trials only in India. We have conducted trials in 12 countries including the UK. We are doing trials in Pakistan, Nepal, Bangladesh and other countries. We are not only an Indian company, we are truly a global company. ‘
  • Created the vaccine for 123 countries: He said, “We are not a company with no experience in making vaccines.” We have a lot of experience in making vaccines. We made vaccines for 123 countries. Our company with such experience is the only one. ‘
  • Read the articles questioning the data: Ella said, ‘Many people are saying that there is no transparency in our data. I think people should be restrained and read the articles we have published on the internet regarding data. So far, more than 70 articles have been published in international journals.
  • Blaming us is not right: He said, ‘Many people are only gossiping on the vaccine, it is a blot on Indian companies. This is not right for us. This should not happen to us. The human clinical trial of the Merek Ebola vaccine was never completed, despite WHO approving it for emergency use for Liberia and Guinea. ‘
  • Don’t know why Indian companies are the target: Krishna Alla said, “I don’t know that Indian companies are always targeted by people all over the world. Whereas, issuing emergency medical licenses is a global practice. America also says that if your immunization data is good then you got emergency approval. May go.’
  • We have 20 million doses ready: He said, “Currently we have 2 crore doses ready. We will soon be able to produce 70 crore doses. These vaccines are being prepared at our four centers. Three of them are in Hyderabad and one in Bangalore. Right now we have many Are facing a variety of challenges. These include the logistic problem. “
  • We have BSL-3 production facility only: He said, ‘It is a matter of pride that we have only BSL-3 production facility all over the world. Even the US does not have this facility. We are there to help in public health emergency, then why should it be in any part of the world. ‘ He said on the new strain of Corona, give us a week’s time. We will confirm the complete data on this issue.
  • Initially the vaccine will be a bit expensive: They said that the vaccine would be a bit expensive in the initial stages. When the production of the vaccine increases, it will be controlled through the price market. We will continue to vaccinate people at the open level and will also monitor safety and efficiency.

Akhilesh Yadav was the first to raise questions
Samajwadi Party President Akhilesh Yadav first questioned this. On Saturday, on social media, it was said that the government which ran away from Corona by clapping the plate cannot be trusted. He said that the BJP cannot trust the government’s system of getting the vaccine, which was lying in the coronary period.

Congress in support of Akhilesh
Congress leader Rashid Alvi supported Akhilesh. He said that just as the BJP and Prime Minister are using the CBI, Income Tax Department and ED against opposition leaders, I feel that Akhilesh Yadav’s fear that the vaccine may also be misused.

Shashi Tharoor and Jairam Ramesh also raised questions
Congress leader Shashi Tharoor said that Kovaxin has not yet completed its third trial. The vaccine is approved in a hurry and can be dangerous. He said that until the trial is over, its use should be avoided.

Jairam Ramesh, another senior party leader, said that Bharat Biotech is a first-rate enterprise, but the surprising thing is that the protocols related to Kovaxin’s Phase-3 trial, which have been approved at the international level, can be modified. Used to be. The Health Minister should answer this.

Government gave reply to opposition

  • Union Health Minister Dr. Harsh Vardhan said that doing politics on such serious issues is quite disappointing. Shashi Tharoor, Akhilesh Yadav and Jairam Ramesh do not try to question the protocol adopted to approve the vaccine.
  • Taking a dig at the opposition’s questions, BJP national president JP Nadda said that the Congress and opposition parties are not proud of anything Indian. He said on social media that he should introspect that his lies on the vaccine would be used to run his illusionist agenda. The people of the country will reject such politics.
  • Taking a dig at the Congress, Union Minister Prakash Javadekar said that earlier he used to ask for proof of Balakot air strike by India. Then Pulwama expresses doubt about the attack and is now questioning the vaccine as well. What is this bankruptcy?

Kovaxin and Kovishield get approval
On Sunday, the Controller General of India (DCGI) approved Bharati Biotech’s Indigenous Kovaxin and Serum Institute’s Emergency Use of Kovishield. At the same time, Zaykov-D of Zydus Cadila Healthcare has received the approval of Phase-3 trial.